{"product_id":"biolegend-504104","title":"Biolegend, 504104, PE anti-mouse IL-4 Antibody, 100μg","description":"\u003cp\u003eIL-4 is a pleiotropic cytokine produced by activated T cells, mast cells, and basophils. IL-4 is a potent lymphoid cell growth factor which stimulates the growth and activation of certain B cells and T cells. IL-4 is important for regulation of T helper subset development.\u003cbr\u003e\n100μg\u003cbr\u003e\nVerified Reactivity: Mouse\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Rat\u003cbr\u003e\nImmunogen: Partially purified native mouse IL-4\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.\u003cbr\u003e\nConcentration: 0.2 mg\/ml\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.\u003cbr\u003e\nApplication: ICFC - Quality tested\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.\u003cbr\u003e\nExcitation Laser: Blue Laser (488 nm)Green Laser (532 nm)\/Yellow-Green Laser (561 nm)\u003cbr\u003e\nApplication Notes: ELISA1,2,10,13 or ELISPOT5 Capture: The purified 11B11 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated BVD6-24G2 antibody (Cat. No. 504202) as the detecting antibody and recombinant mouse IL-4 (Cat. No. 575609) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture.Neutralization1-2,9,12: The 11B11 antibody can neutralize the bioactivity of natural or recombinant IL-4. The LEAF™ purified antibody (Endotoxin \u0026lt;0.1 EU\/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IL-4 bioactivity in vivo and in vitro (Cat. No. 504108).Additional reported applications (for the relevant formats) include: immunoprecipitation16, immunohistochemical staining of formalin-fixed paraffin-embedded tissue sections8 and paraformaldehyde-fixed, saponin-treated frozen tissue sections6,7, and immunocytochemistry4.Note: For testing mouse IL-4 in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 431101 to 431106) are specially developed and recommended.\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Shirai A, et al. 1994. Cytokine 6:329. (ELISA, Neut) Abrams J. 1995. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.20. (ELISA, Neut) Assenmacher M, et al. 1994. Eur. J. Immunol. 24:1097. Openshaw P, et al. 1995. J. Exp. Med. 182:1357. (ICC) Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.19. (ELISA Capture) Litton M, et al. 1994. J. Immunol. Methods 175:47. (IHC) Andersson U, et al. 1999. Detection and quantification of gene expression. New York:Springer-Verlag. (IHC) Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC) Hara M, et al. 2001. J. Immunol. 166:3789. (Neut) Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA) Lawson BR, et al. 2007. J. Immunol. 178:5366. Wang W, et al. 2007. J. Immunol. 178:4885. (Neut) Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed Ohnmacht C, et al. 2008. Blood 113:2816. PubMed Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed Zavorotinskaya T, et al. 2003. Mol. Ther. 7:155. (IP)\u003cbr\u003e\nProduct Citations: Kim K, et al. 2016. PLoS One. 11: 0148576. PubMed Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed Dai L, et al. 2020. Cell. 182(3):722-733.e11. PubMed Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed Wang X, et al. 2019. Cell Res. 29:787. PubMed Du J, et al. 2022. Sci Immunol. 7:eabo5407. PubMed Aso K, et al. 2023. Nat Commun. 14:984. PubMed Choi BJ, et al. 2023. Nat Commun. 14:1631. PubMed van Os BW, et al. 2023. Eur Heart J Open. 3:oead013. PubMed Wang X, et al. 2023. Nat Commun. 14:3440. PubMed Wang Z, et al. 2023. Sci Adv. 9:eabo4100. PubMed Zhou Y, et al. 2021. Methods Mol Biol. 2388:35. PubMed Qu L, et al. 2022. Cell. 185:1728. PubMed Lu R, et al. 2022. Scand J Immunol. 96:e13177. PubMed Zhu M, et al. 2022. Front Immunol. 13:1019248. PubMed Schepers M, et al. 2023. Brain Behav Immun. 109:1. PubMed Ai L, et al. 2023. Cell Discov. 9:9. PubMed Gerber AN, et al. 2021. Cell Rep. 37:109816. PubMed Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed Lua Y, et al. 2012. Mol Immunol. 52:229. PubMed Su N, Xiong Y 2016. Sci Rep. 6:22658. PubMed Sanchez-Felipe L, et al. 2021. Nature. 590:320. PubMed Wei H, et al. 2021. Malar J. 20:89. PubMed Turner JA, et al. 2020. Immunity. 53:1202. PubMed Amir M, et al. 2018. Cell Rep. 25:3733. PubMed Lu Y, et al. 2019. Int J Mol Med. 43:2398. PubMed Zhang C, et al. 2022. J Extracell Vesicles. 11:e12209. PubMed Volpedo G, et al. 2022. NPJ Vaccines. 7:32. PubMed Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed Jiang S, et al. 2020. Scand J Immunol. e12867:91. PubMed Kohu K, et al. 2009. J Immunol. 183:7817. PubMed Sasaki K, et al. 2019. Nat Commun. 10:3878. PubMed Tritama E, et al. 2018. Hum Vaccin Immunother. 14:1524. PubMed Cao W, et al. 2017. Immunity. 47:1182. PubMed Green CD et al. 2018. Developmental cell. 46(5):651-667 . PubMed Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed Wu G, et al. 2020. Br J Pharmacol. 177:5063. PubMed Tuganbaev T, et al. 2020. Cell. 182(6):1441-1459.e21. PubMed Shiomi A, et al. 2014. J Immunol. 193:849. PubMed Sawant D, et al. 2014. J Immunol. 192:2904. PubMed Trompette A, et al. 2022. Mucosal Immunol. :. PubMed Ikeda U, et al. 2010. Immunol Lett. 134:7. PubMed Bhattacharya D, et al. 2014. J Biol Chem. 289:16508. PubMed Bogie JF, et al. 2020. Ther Adv Chronic Dis. 11:2040622320947378. PubMed Liao T, et al. 2017. Front Immunol. 8:1334. PubMed Imani J, et al. 2021. JCI Insight. 6:. PubMed Coe D, et al. 2022. JCI Insight. 7:. PubMed Wang Z, et al. 2022. Nat Biomed Eng. 6:791. PubMed Harb H, et al. 2021. Immunity. 54(6):1186-1199.e7. PubMed Yang J, et al. 2022. Microbiome. 10:149. PubMed Chung NH, et al. 2022. Vaccine. 40:574. PubMed Yuan Y, et al. 2022. Cell Rep. 38:110256. PubMed Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed Kim DH, et al. 2018. Nat Commun. 9:503. PubMed Yang B, et al. 2022. Bioengineered. 13:2685. PubMed Daneshmandi S, et al. 2021. Elife. 10:. PubMed Ma X, et al. 2020. Immunity. 53:1315. PubMed Fu S, et al. 2020. Nat Commun. 0.7625. PubMed Dudeck J, et al. 2019. J Allergy Clin Immunol. 143:1849. PubMed Tajima M, et al. 2022. Curr Protoc. 2:e540. PubMed Choi J, et al. 2015. PLoS One. 10: e0138592. PubMed Xiao u, et al. 2015. J Immunol. 195: 4218 - 4227. PubMed Miura N, et al. 2017. Mol Ther. 10.1016\/j.ymthe.2017.01.020. PubMed Fernández-Orth J, et al. 2020. Eur J Immunol. . PubMed Harb H, et al. 2020. Nat Immunol. 1359:21. PubMed Chan Y, et al. 2009. J Immunol. 183:7039. PubMed Ji L et al. 2019. Immunity. 51(2):272-284 . PubMed Tian D, et al. 2019. Nat Commun. 10:4246. PubMed Ma Q, et al. 2022. Vaccines (Basel). 10:. PubMed Xu Y, et al. 2021. iScience. 24:103445. PubMed Huang LJ, et al. 2021. Immunity. 54(8):1728-1744.e7. PubMed Xu C, et al. 2021. Cell Reports. 35(11):109235. PubMed Mykkänen O, et al. 2014. PLoS One. 9:114790. PubMed Zeng J, et al. 2020. Int J Biol Sci. 1.939583333. PubMed Nomura S, et al. 2019. Sci Rep. 9:17335. PubMed Wang N, et al. 2020. Front Immunol. 1.765972222. PubMed Muri J, et al. 2020. Cell Reports. 30(13):4399-4417. PubMed Brenner E, et al. 2020. Nat Commun. 11:1335. PubMed Bing Wu et al. 2018. Immunity. 49(5):886-898 . PubMed\u003cbr\u003e\nRRID: AB_315317 (BioLegend Cat. No. 504103) AB_315318 (BioLegend Cat. No. 504104)\u003cbr\u003e\nStructure: Cytokine; 15-19 kD (Mammalian)\u003cbr\u003e\nBioactivity: Differentiation of naïve CD4+ T cells to the TH2 type, proliferation\/differentiation of activated B cells, expression of class II MHC antigens, and of low affinity IgE receptors in resting B cells\u003cbr\u003e\nCell Sources: Mast cells, T cells, bone marrow stromal cells\u003cbr\u003e\nCell Targets: B cells, T cells, monocytes, endothelial cells, fibroblasts\u003cbr\u003e\nReceptors: Heterodimer IL-4Rα (CD124); γ-subunit (CD132) in common with IL-2R, IL-7R, IL-13R, IL-15R\u003cbr\u003e\nCell Type: Tregs\u003cbr\u003e\nBiology Area: Immunology\u003cbr\u003e\nMolecular Family: Cytokines\/Chemokines\u003cbr\u003e\nAntigen References: 1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego. 2. Boulay J, et al. 1992. Curr. Opin. Immunol. 4:294. 3. Dullens H, et al. 1991. In vivo 5:567. 4. Paul W. 1991. Blood 77:1859.\u003cbr\u003e\nRegulation: Upregulated by IL-2, platelet activating factor; downregulated by TGF-β\u003cbr\u003e\nGene ID: 16189\u003cbr\u003e\nUniProt: View information about IL-4 on UniProt.org\u003cbr\u003e\nClone: 11B11\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: Interleukin-4, Ia inducing factor (IaIF), B cell stimulating factor-1 (BSF-1), Hodgkin's cell growth factor (HCGF), Mast cell growth factor-2 (MCGF-2), Macrophage fusion factor (MFF), T cell growth factor-2 (TCGF-2)\u003cbr\u003e\nIsotype: Rat IgG1, κ\u003cbr\u003e\nQ: What type of PE do you use in your conjugates?\u003cbr\u003e\nA: We use R-PE in our conjugates.\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46860790497449,"sku":"504104","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/es\/products\/biolegend-504104","provider":"Iright","version":"1.0","type":"link"}